Recent News

• 03.03.2025 - Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
• 03.03.2025 - Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
• 02.11.2025 - Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
• 01.13.2025 - Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation P
• 01.13.2025 - Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
• 01.13.2025 - 42nd Annual J.P. Morgan Healthcare Conference
• 01.07.2025 - Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
• 01.07.2025 - Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
• 12.16.2024 - Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
• 12.06.2024 - Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

Recent Filings